Safety evaluation during deep-brain magnetic stimulation (DMS)treating motor symptoms in Parkinsonian rats

doi:10.3969/j.issn.1006-7795.2017.02.020

Abstract

Abstract: Objective To explore the security via DMS to treat motor symptoms in hemi-parkinsonian rats.Methods Rats were injected with 6-hydroxydopamine (6-OHDA) into right striatum to establish unilateral parkinsonian model. Sham group received the same volume of normal saline by the same procedure. After screened via apomorphine, the successful parkinsonian rats were randomly grouped into model, δ rhythm DMS treatment (DMS-δ) and γ rhythm DMS treatment (DMS-γ). Among each DMS treatment group, 40 minutes trains of DMS were administered daily for 4 weeks. Cylinder tests were conducted to detect motor outcomes. Body weight determination, peripheral blood lymphocytes classification & counting, HE staining were executed to evaluate the security of DMS. Results 1The lesioned side forelimb usage ratio in Sham and DMS-γ groups were significantly higher than that in Model group. 2There was no significant difference of body weight between each group, indicating that DMS had no significant effects on body weight. 3There was no significant difference of the number and percentage of total lymphocytes & T cells between each group, while the natural killer (NK) cells number and percentage in DMS-δ group were significantly higher than that in Model group. 4Results of HE staining for major organs showed no significant histopathological change. Conclusion DMS-γ treatment alleviated bilateral limb asymmetry in PD rats. Meanwhile, DMS treatment showed no significant side effects, indicating that DMS showed satisfactory security in the treatment of motor symptoms in PD rats.

Key words: Parkinson's disease, deep-brain magnetic stimulation, motor behavior, side effects, safety

CLC Number:

R742.5

Liu Junhua, Wang Yong, Wang Yanyan, Wang Xiaomin. Safety evaluation during deep-brain magnetic stimulation (DMS)treating motor symptoms in Parkinsonian rats[J]. Journal of Capital Medical University, 2017, 38(2): 260-267.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2017.02.020

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2017/V38/I2/260

References

[1] Dauer W, Przedborski S. Parkinson's disease: mechanisms and models[J]. Neuron, 2003,39(6):889-909.
[2] Braak H, Del Tredici K. Cortico-basal ganglia-cortical circuitry in Parkinson's disease reconsidered[J]. Exp Neurol,2008, 212(1):226-229.
[3] Obeso J A, Rodriguez-Oroz M C, Goetz C G, et al. Missing pieces in the Parkinson's disease puzzle[J]. Nat Med,2010,16(6):653-661.
[4] Moldovan A S, Groiss S J, Elben S, et al. The treatment of parkinson's disease with deep brain stimulation: current issues[J]. Neural Regen Res,2015,10(7):1018-1022.
[5] Baizabal-Carvallo J F, Jankovic J. Movement disorders induced by deep brain stimulation[J]. Parkinsonism Relat Disord,2016(25):1-9.
[6] Fitzgerald P B, Daskalakis Z J. The effects of repetitive transcranial magnetic stimulation in the treatment of depression[J]. Expert Rev Med Devices,2011,8(1):85-95.
[7] Bentwich J, Dobronevsky E, Aichenbaum S, et al. Beneficial effect of repetitive transcranial magnetic stimulation combined with cognitive training for the treatment of Alzheimer's disease: a proof of concept study[J]. J Neural Transm (Vienna),2011,118(3):463-471.
[8] Deng Z D, Lisanby S H, Peterchev A V. Electric field depth-focality tradeoff in transcranial magnetic stimulation: simulation comparison of 50 coil designs[J]. Brain Stimul,2013,6(1):1-13.
[9] Chen R, Gerloff C, Classen J, et al. Safety of different inter-train intervals for repetitive transcranial magnetic stimulation and recommendations for safe ranges of stimulation parameters[J]. Electroencephalogr Clin Neurophysiol,1997,105(6):415-421.
[10] Wassermann E M. Risk and safety of repetitive transcranial magnetic stimulation: report and suggested guidelines from the International Workshop on the Safety of Repetitive Transcranial Magnetic Stimulation, June 5-7, 1996[J]. Electroencephalogr Clin Neurophysiol,1998,108(1):1-16.
[11] Zhang Y, Mao R R, Chen Z F, et al. Deep-brain magnetic stimulation promotes adult hippocampal neurogenesis and alleviates stress-related behaviors in mouse models for neuropsychiatric disorders[J]. Mol Brain,2014(7):11.
[12] Blandini F, Armentero M T. Animal models of Parkinson's disease[J]. FEBS J,2012,279(7):1156-1166.
[13] Ma Y, Zhan M, OuYang L, et al. The effects of unilateral 6-OHDA lesion in medial forebrain bundle on the motor, cognitive dysfunctions and vulnerability of different striatal interneuron types in rats[J]. Behav Brain Res,2014(266):37-45.
[14] Iderberg H, McCreary A C, Varney M A, et al. NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat[J]. Exp Neurol,2015,271:335-350.
[15] Domecq J P, Prutsky G, Leppin A, et al. Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis[J]. J Clin Endocrinol Metab,2015,100(2):363-370.
[16] Matsunaga S, Osawa T, Geshi M, et al. Effect of a single intrauterine administration of recombinant bovine interferon-T on day 7 of the estrous cycle on the luteal phase length and blood profile in dairy cows[J]. Res Vet Sci,2012,93(1):381-385.
[17] Zhou S, Zhang B, Liu X, et al. A new natural angelica polysaccharide based colon-specific drug delivery system[J]. J Pharm Sci,2009,98(12):4756-4768.
[18] de Alencar N M, da Silveira Bitencourt F, de Figueiredo I S, et al. Side-Effects of Irinotecan (CPT-11), the Clinically Used Drug for Colon Cancer Therapy, Are Eliminated in Experimental Animals Treated with Latex Proteins from Calotropis procera (Apocynaceae)[J]. Phytother Res,2017,31(2):312-320.
[19] Cooper M D. The early history of B cells[J]. Nat Rev Immunol,2015,15(3):191-197.
[20] Popko K, Gorska E. The role of natural killer cells in pathogenesis of autoimmune diseases[J]. Cent Eur J Immunol,2015,40(4):470-476.
[21] Spitaels J, Roose K, Saelens X. Influenza and memory T cells: how to awake the force[J]. Vaccines (Basel),2016,4(4)Pii: E33.
[22] Shrestha R, Shakya Shrestha S, Millingtona O, et al. Immune responses in neurodegenerative diseases[J]. Kathmandu Univ Med J (KUMJ),2014,12(45):67-76.